Last $3.72 USD
Change Today +0.04 / 1.09%
Volume 123.0K
PSDV On Other Exchanges
As of 5:20 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/17/14 - $5.45
52 Week Low
10/31/13 - $2.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics in the United States and the United Kingdom. The company develops its products based on its Durasert and Tethadur drug delivery technologies focusing on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company also provides Medidur, an injectable, sustained-release micro-insert designed to treat non-infectious uveitis affecting the posterior segment of the eye, which is in Phase III clinical trial.It has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

24 Employees
Last Reported Date: 09/11/14
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $728.3K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $302.7K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $466.4K
Compensation as of Fiscal Year 2013.

psivida corp (PSDV) Key Developments

pSivida Corp. Reports FDA Approval of ILUVIEN(R) for Diabetic Macular Edema

pSivida Corp. announced that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN(R) for the treatment of diabetic macular edema (DME). It is indicated for patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). A single injection of the ILUVIEN micro-insert provides sustained treatment of DME for 36 months. Approximately 560,000 people in the U.S. are estimated to have clinically significant DME, the most frequent cause of vision loss in individuals with diabetes and a cause of blindness in young and middle-aged adults in developed countries. ILUVIEN is expected to be commercially available in the U.S. in early 2015. ILUVIEN is an injectable micro-insert that provides sustained treatment through continuous delivery of a submicrogram dose of the corticosteroid fluocinolone acetonide for 36 months. Current standard-of-care therapy requires anti-VEGF injections into the eye as frequently as monthly, and studies show that over 50% of patients are not optimally managed with this treatment. FDA approval was based on clinical trial data that showed that at month 24, 28.7% of patients receiving ILUVIEN experienced an improvement from baseline in their best corrected visual acuity on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart of 15 letters or more. This improvement in vision was maintained through 36 months, the end of the trials.

pSivida Corp. Names James J. Barry, Ph.D. to its Board of Directors

pSivida Corp. reported that it has elected James J. Barry, Ph.D. to its Board of Directors. The company announced thar Barry currently serves as Executive Vice President and Chief Operating Officer of InspireMD. At InspireMD, Barry is responsible for advancing the product pipeline, managing all global clinical trial activities and driving the operational activities. He also serves as a director of InspireMD.

pSivida Corp. Names James J. Barry to Board of Directors

pSivida Corp. announced that it has elected James J. Barry to its Board of Directors. Dr. Barry, currently serves as Executive Vice President and Chief Operating Officer of InspireMD. Dr. Barry currently serves on a number of advisory boards including the College of Biomedical Engineering at Yale University, the College of Sciences at University of Massachusetts-Lowell and the Massachusetts Life Science Center.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $3.72 USD +0.04

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $179.25 USD +1.76
Regeneron Pharmaceuticals Inc $366.13 USD -3.52
View Industry Companies

Industry Analysis


Industry Average

Valuation PSDV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.0x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at